title: [Experimental therapeutic effects of hybrid liposomes on the Alzheimer's disease in vitro].
abstract: Accumulation of β amyloid (Aβ) peptides to nerve cells should be associated with the onset of Alzheimer's disease (AD). We prepared hybrid liposomes (HL) composed of 90 mol% phospholipids having various charged head groups (cationic L-α-dimyristoyltrimethyl ammonium propane (DMTAP), anionic L-α-dimyristoylphosphatidylserine (DMPS) or zwitterionic L-α-dimyristoylphosphatidylcholine (DMPC)) and 10 mol% polyoxyethylene(23) dodecyl ether (C(12)(EO)(23))), and investigated the inhibitory effects of HL on the accumulation of Aβ(1-40) peptides into human neuroblastoma (SH-SY5Y) cells in vitro. It is noteworthy that remarkable inhibitory effects on the accumulation of Aβ(1-40) peptides were observed for SH-SY5Y cells treated with anionic HL-DMPS, though the accumulation was not inhibited by cationic HL-DMTAP. On the other hand, the immediate fusion of HL-DMTAP into SH-SY5Y cells was confirmed using a confocal laser microscope. Interestingly, the specific interactions between anionic HL-DMPS and Aβ(1-40) peptides were observed using the thioflavin T (ThT) assay. In addition, the cytotoxicity of Aβ(1-42) peptides on the SH-SY5Y cells decreased after the treatment with HL-DMPS. These results suggest that anionic HL-DMPS could be used as a novel medicine for AD in the future.
authors.affiliation: Division of Applied Life Science, Graduate School of Engineering, Sojo University, Kumamoto, Japan.
authors.forename: Keiko
authors.initials: K
authors.lastname: Zako
authors.forename: Maki
authors.initials: M
authors.lastname: Sakaguchi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Komizu
authors.forename: Hideaki
authors.initials: H
authors.lastname: Ichihara
authors.forename: Koichi
authors.initials: K
authors.lastname: Goto
authors.forename: Yoko
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Ueoka
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000838:Anions; D003864:Depression, Chemical; D006801:Humans; D008081:Liposomes / Q000494:pharmacology* / Q000627:therapeutic use; D009447:Neuroblastoma / Q000378:metabolism* / Q000473:pathology*; D010446:Peptide Fragments / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D014494:Unithiol / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D016229:Amyloid beta-Peptides; D000838:Anions; D008081:Liposomes; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40); D014494:Unithiol